When advisers first start looking at business relief (BR) products, there is much to take in: the rules governing such products; the investment strategies being used; and what the investment risk is. It is easy to lose sight of the fact that, for non-AIM products, the investment is being made directly into a company or partnership, rather than a fund. It is, therefore, essential that governance is part of the diligence process.
02 Jul 2019
THE MONTHLY July 2019
Advanced Oncotherapy Plc (AVO:LON), 1.9 | AJ Bell Plc (AJB:LON), 298 | Allergy Therapeutics plc (AGY:LON), 2.8 | Arbuthnot Banking Group PLC (ARBB:LON), 1,065 | City of London Investment Group PLC (CLIG:LON), 318 | DP Poland PLC (DPP:LON), 12.8 | Gateley (Holdings) Plc (GTLY:LON), 123 | Koovs (KOOV:LON), 0 | Lightwaverf (LWRF:LON), 0 | Murgitroyd Group (MUR:LON), 0 | Oxford BioMedica plc (OXB:LON), 188 | Palace Capital plc (PCA:LON), 228 | Primary Health Properties PLC (PHP:LON), 91.2 | R.E.A. Holdings plc (RE:LON), 70.2 | Redx Pharma Plc (REDX:LON), 21.5 | RM Infrastructure Income PLC GBP (RMII:LON), 75.2 | Shield Therapeutics Plc (STX:LON), 2.1 | 600 Group PLC (SIXH:LON), 2.6 | Tissue Regenix Group plc (TRX:LON), 68.0 | Titon Holdings Plc (TON:LON), 80.0 | Urban Logistics REIT plc (SHED:LON), 116 | Volta Finance Limited (VTA:LON), 512 | Warpaint London PLC (W7L:LON), 415 | ValiRx PLC (VAL:LON), 3.8
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
THE MONTHLY July 2019
Advanced Oncotherapy Plc (AVO:LON), 1.9 | AJ Bell Plc (AJB:LON), 298 | Allergy Therapeutics plc (AGY:LON), 2.8 | Arbuthnot Banking Group PLC (ARBB:LON), 1,065 | City of London Investment Group PLC (CLIG:LON), 318 | DP Poland PLC (DPP:LON), 12.8 | Gateley (Holdings) Plc (GTLY:LON), 123 | Koovs (KOOV:LON), 0 | Lightwaverf (LWRF:LON), 0 | Murgitroyd Group (MUR:LON), 0 | Oxford BioMedica plc (OXB:LON), 188 | Palace Capital plc (PCA:LON), 228 | Primary Health Properties PLC (PHP:LON), 91.2 | R.E.A. Holdings plc (RE:LON), 70.2 | Redx Pharma Plc (REDX:LON), 21.5 | RM Infrastructure Income PLC GBP (RMII:LON), 75.2 | Shield Therapeutics Plc (STX:LON), 2.1 | 600 Group PLC (SIXH:LON), 2.6 | Tissue Regenix Group plc (TRX:LON), 68.0 | Titon Holdings Plc (TON:LON), 80.0 | Urban Logistics REIT plc (SHED:LON), 116 | Volta Finance Limited (VTA:LON), 512 | Warpaint London PLC (W7L:LON), 415 | ValiRx PLC (VAL:LON), 3.8
- Published:
02 Jul 2019 -
Author:
Brian Moretta -
Pages:
37
When advisers first start looking at business relief (BR) products, there is much to take in: the rules governing such products; the investment strategies being used; and what the investment risk is. It is easy to lose sight of the fact that, for non-AIM products, the investment is being made directly into a company or partnership, rather than a fund. It is, therefore, essential that governance is part of the diligence process.